Nestlé Health Science announces staged acquisition of Phagenesis, an Inventages portfolio company

Nestlé Health Science (NHSc) and Phagenesis announced today that NHSc is entering into a staged, milestone-based acquisition of Phagenesis, a medical device company that has developed a new treatment for dysphagia.

Under the terms of the agreement, NHSc will make an upfront payment, followed by milestone-based funding, while Phagenesis completes the clinical evaluation of Phagenyx®. The staged acquisition will be based upon successful completion of European and US development programs anticipated by 2019. Financial terms have not been disclosed.

To read the full press release, visit: http://www.phagenesis.com/news/the-staged-acquisition-of-phagenesis-by-nestle-health-science-will-benefit-patients-with-dysphagia